Effects of Non-Alcoholic Fatty Liver Disease on Baseline Histology and 96-Week Entecavir Response in Treatment-Naïve Chronic Hepatitis B
Xiaohui Gu, Weiguang Yang, Yue Hu, Yixin Li, Liwei Zheng, Bei Jiang · 2025
Read Effects of Non-Alcoholic Fatty Liver Disease on Baseline Histology and 96-Week Entecavir Response in Treatment-Naïve Chronic Hepatitis B by Xiaohui Gu, Weiguang Yang, Yue Hu, Yixin Li, Liwei Zheng, Bei Jiang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12743469.txt.
Description
Xiaohui Gu and co-authors examine how fatty liver disease changes the course of chronic hepatitis B treatment, in a 2025 study. The two liver conditions now often occur in the same patient. Fatty liver may blunt the effect of antiviral drugs. Evidence on that interaction has stayed unclear.
About three hundred patients starting entecavir were followed at a Chinese hospital. Roughly half also had fatty liver disease, confirmed by biopsy or ultrasound. The team compared liver tissue traits at the start. They tracked virus suppression over ninety-six weeks of therapy. Differences between the groups inform how doctors counsel patients. Weight and metabolic care may matter alongside antiviral pills. The cohort adds real-world weight to the debate.
Catalog record
| CREATOR | Xiaohui Gu, Weiguang Yang, Yue Hu, Yixin Li, Liwei Zheng, Bei Jiang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |